Skip to main content
OPEN

Establishing Ortho and Cardiology Ambulatory Surgical Centres in Europe

Last Updated: 8/4/2025Deadline: 29 April 2026€37.2M Available

Quick Facts

Programme:Horizon Europe
Call ID:HORIZON-JU-IHI-2025-11-05-
Deadline:29 April 2026
Max funding:€37.2M
Status:
open
Time left:9 months

💰 Funding Details

Funding Description – HORIZON-JU-IHI-2025-11-05


Core Facts

* Call Identifier: HORIZON-JU-IHI-2025-11-05 (two-stage)

* Type of Action: Research & Innovation Action (RIA) under the Innovative Health Initiative Joint Undertaking (IHI-JU)

* Total Topic Budget: €37.209 million (IHI-JU contribution)

* Indicative Grant Size: ~€10–13 million EC funding per project (1 grant expected)

* EU Funding Rate: 100 % of eligible direct costs + 25 % indirect costs (Horizon Europe rules)

* Industry Co-Contribution: IHI projects must reach ≥45 % total project costs from industry & contributing partners (cash or in-kind).

* Submission Windows:

* Stage 1 short proposal (max 20 pages): deadline 09 Oct 2025, 17:00 CET

* Stage 2 full proposal (max 50 pages): deadline 29 Apr 2026, 17:00 CET

* Project Start: Q4 2026 (indicative) — duration typically 48–60 months.


What the Grant Funds

The action finances integrated R&I work that accelerates the roll-out of Ambulatory Surgical Centres (ASCs) specialised in orthopaedics (hip/knee arthroplasty) and cardiology (cardiac ablation/elective rhythmology) across Europe. Eligible cost categories include (non-exhaustive):

* Clinical evidence generation – two multicentre cohort studies comparing ASC vs. hospital outcomes.

* Digital infrastructure – interoperable IT solutions, data integration layers, patient-facing apps, EHDS-ready architectures.

* Registries & Real-World Evidence (RWE) platforms for clinical-economic data capture.

* Training & capacity building for surgeons, anaesthetists, nurses, admin staff.

* Multistakeholder advisory board operations, consensus workshops, HTA & payer engagement.

* Development of coding/reimbursement models, policy briefs, and economic modelling.

* Network coordination among pilot ASCs, exchange of SOPs & best practices.

* Dissemination, communication, exploitation, and sustainability work (incl. business models for ASC scale-up).


Eligibility Snapshot

* Consortium minimum: 3 independent legal entities from 3 different EU Member States or Horizon-Europe Associated Countries.

* Ineligible for funding: entities established in UK & Canada (may participate at own cost).

* Recommended partners:

* University & teaching hospitals with ortho/cardiology departments

* Existing ASC operators (public or private)

* MedTech & digital health industry (incl. IHI corporate members)

* Patient organisations & carer associations

* Payers / HTA / reimbursement agencies

* Standards & certification bodies

* Ethics & Data: proposals containing clinical studies must annex the “Essential information for clinical studies”; GDPR & EHDS compliance mandatory.


Key Grant Conditions

* Two-stage evaluation (Excellence, Impact, Quality).

* Use the IHI specific Part B templates and mandatory annexes (Type of Participants, IKOP/IKAA tables, Declaration of in-kind commitment, Clinical Studies, Ethics).

* Model Grant Agreement: Horizon Europe General MGA v1.2 with IHI-JU options (incl. JU right to object to transfer/licensing).

* No 3A (Availability, Accessibility, Affordability) obligation for this topic.


Added Value for Beneficiaries

* Early mover advantage in the fast-growing European ASC market.

* Direct shaping of reimbursement frameworks and clinical standards.

* Long-term exploitation possibilities for MedTech, digital & data analytics SMEs.

* Contribution to EU policy priorities (EHDS, AI Act, SRIA) and hospital decongestion.

Personalizing...

📊 At a Glance

€37.2M
Max funding
29 April 2026
Deadline
9 months
Time remaining
Eligible Countries
EU Member States, Associated Countries

🇪🇺 Strategic Advantages

EU-Wide Advantages & Opportunities for "Establishing Ortho and Cardiology Ambulatory Surgical Centres in Europe"


1. Health-system Transformation at Continental Scale

Rapid capacity relief for overstretched hospitals in all Member States by shifting high-volume orthopaedic and cardiology procedures to ASCs.

• Harmonised ASC models allow benchmarking across borders, accelerating adoption of best practices and reducing unwarranted clinical variation EU-wide.


2. Economies of Scale & Joint Purchasing Power

• Pan-European network enables bulk procurement of medical devices, IT platforms and e-health solutions, lowering unit costs (particularly relevant for implants, ablation catheters, remote monitoring kits).

• Shared training curricula, simulation centres and e-learning modules reduce duplication and spread fixed costs over a larger talent pool.


3. Single Digital Market & European Health Data Space (EHDS) Alignment

• Cross-border ASC registry creates one of Europe’s first multi-country, GDPR-compliant datasets on orthopaedic and electrophysiology outcomes, feeding directly into EHDS.

• Interoperable IT architecture piloted here can serve as a reference implementation for MyHealth@EU services, fostering vendor neutrality and portability.


4. Accelerated Evidence Generation & HTA Convergence

• Multicentre cohorts from different reimbursement cultures deliver robust real-world evidence (RWE) accepted by several national HTA bodies simultaneously, shortening time-to-coverage for novel techniques.

• Facilitates joint HTA dossiers under Regulation (EU) 2021/2282, reducing administrative burden for innovators and payers.


5. Workforce Mobility & Skills Agenda

• EU-level certification pathways for ASC-specific roles (nurse-led clinics, peri-operative coordinators, data officers) promote mutual recognition of qualifications and support the Pact for Skills in health.

• Attractive cross-border career tracks help retain talent in less populous regions, mitigating the North–South / urban-rural brain drain.


6. Regulatory Sandboxing & AI Act Readiness

• Project offers a controlled, multi-jurisdictional environment to test AI-enabled decision support (triage, risk-stratification) under the new EU AI Act before broader roll-out.

• Early dialogue with Notified Bodies and Competent Authorities across several countries speeds up CE-marking of ASC-tailored devices.


7. Cohesion Policy & Regional Development

• Rural and cohesion regions can host satellite ASCs, leveraging EU Structural Funds for infrastructure while the Horizon grant funds the innovation layer, thus stacking EU instruments for maximum impact.

• Creates local high-skill jobs and stimulates smart specialisation in MedTech and digital health clusters.


8. Sustainability & Green Deal Contributions

• Same-day discharge reduces inpatient energy consumption and waste; aggregated EU data enables carbon footprint benchmarking across sites, informing future EU taxonomy criteria for sustainable healthcare.

• Joint procurement can stipulate eco-design requirements for single-use devices, influencing manufacturers at continental scale.


9. Strategic Autonomy & Competitiveness of EU Health Industry

• Establishes a home market of >450 million citizens for EU-made ASC equipment, strengthening domestic supply chains and reducing dependence on imports.

• Demonstrator for integrated care pathways boosts Europe’s credibility in exporting health service innovation to other regions.


10. Funding Leverage & Complementarity

• Horizon-IHI funds research & coordination; InvestEU, ERDF and national resilience plans can co-finance bricks-and-mortar ASC build-out.

• Synergies with EU4Health, Digital Europe and Erasmus+ enlarge impact (digital literacy, cybersecurity, professional exchanges).


11. Consortium Opportunities

• Ideal to assemble a triple-helix consortium:

• University hospitals & regional health authorities from ≥3 Member States.

• MedTech & digital SMEs/large industry providing implants, mapping systems, RPM platforms.

• Patient organisations and payer/HTA bodies ensuring patient-centred design & reimbursement alignment.

• Inclusion of countries with varying maturity (Nordic outpatient leaders, Southern/Eastern cohesion regions) maximises learning gradient and EU added value.


---

Delivering these advantages at EU scale multiplies impact far beyond what any single Member State could achieve, positioning Europe as the global frontrunner in high-value, patient-centred ambulatory surgical care.

🏷️ Keywords

Topic
Open For Submission